Cypress Advisory Group LLC Invests $1.42 Million in The Cigna Group (NYSE:CI)

Cypress Advisory Group LLC acquired a new stake in shares of The Cigna Group (NYSE:CI - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 5,157 shares of the health services provider's stock, valued at approximately $1,424,000. The Cigna Group accounts for 1.3% of Cypress Advisory Group LLC's portfolio, making the stock its 25th biggest holding.

Several other hedge funds also recently bought and sold shares of CI. Garden State Investment Advisory Services LLC bought a new stake in The Cigna Group during the 3rd quarter valued at about $444,000. Advisory Resource Group increased its position in shares of The Cigna Group by 2.0% during the third quarter. Advisory Resource Group now owns 13,163 shares of the health services provider's stock worth $4,560,000 after acquiring an additional 263 shares during the period. Virtu Financial LLC raised its stake in shares of The Cigna Group by 39.6% during the third quarter. Virtu Financial LLC now owns 17,173 shares of the health services provider's stock valued at $5,949,000 after acquiring an additional 4,870 shares in the last quarter. Te Ahumairangi Investment Management Ltd boosted its holdings in shares of The Cigna Group by 7.9% in the third quarter. Te Ahumairangi Investment Management Ltd now owns 20,330 shares of the health services provider's stock valued at $7,003,000 after purchasing an additional 1,490 shares during the period. Finally, Pine Valley Investments Ltd Liability Co grew its position in shares of The Cigna Group by 28.3% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 15,713 shares of the health services provider's stock worth $5,444,000 after buying an additional 3,466 shares in the last quarter. Institutional investors own 86.99% of the company's stock.

The Cigna Group Trading Up 0.9 %

Shares of CI stock opened at $340.21 on Thursday. The firm's 50 day moving average price is $322.13 and its two-hundred day moving average price is $310.45. The company has a quick ratio of 0.72, a current ratio of 0.66 and a debt-to-equity ratio of 0.70. The Cigna Group has a fifty-two week low of $262.03 and a fifty-two week high of $370.83. The stock has a market cap of $93.11 billion, a price-to-earnings ratio of 27.79, a price-to-earnings-growth ratio of 0.98 and a beta of 0.51.

The Cigna Group (NYSE:CI - Get Free Report) last posted its earnings results on Thursday, January 30th. The health services provider reported $6.64 EPS for the quarter, missing analysts' consensus estimates of $7.84 by ($1.20). The Cigna Group had a return on equity of 18.61% and a net margin of 1.39%. During the same quarter last year, the firm earned $6.79 EPS. On average, analysts anticipate that The Cigna Group will post 29.77 EPS for the current year.

The Cigna Group Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 18th. Shareholders of record on Tuesday, June 3rd will be paid a dividend of $1.51 per share. The ex-dividend date of this dividend is Tuesday, June 3rd. This represents a $6.04 dividend on an annualized basis and a yield of 1.78%. The Cigna Group's dividend payout ratio (DPR) is 49.35%.

Analyst Ratings Changes

A number of research firms recently weighed in on CI. Piper Sandler reaffirmed an "overweight" rating and issued a $348.00 price objective (down from $394.00) on shares of The Cigna Group in a research note on Monday, February 3rd. Royal Bank of Canada set a $355.00 price target on The Cigna Group in a report on Friday, January 31st. Sanford C. Bernstein cut The Cigna Group from an "outperform" rating to a "market perform" rating and set a $323.00 price objective for the company. in a research note on Thursday, February 6th. Guggenheim began coverage on shares of The Cigna Group in a research report on Wednesday, April 9th. They issued a "buy" rating and a $384.00 price objective on the stock. Finally, Barclays cut their price target on shares of The Cigna Group from $420.00 to $339.00 and set an "overweight" rating on the stock in a report on Friday, January 31st. Two research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $373.56.

Insider Transactions at The Cigna Group

In related news, CEO David Cordani sold 26,527 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $308.12, for a total value of $8,173,499.24. Following the sale, the chief executive officer now owns 127,767 shares of the company's stock, valued at approximately $39,367,568.04. This trade represents a 17.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Nicole S. Jones sold 4,904 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $308.12, for a total value of $1,511,020.48. Following the completion of the sale, the insider now directly owns 29,421 shares in the company, valued at $9,065,198.52. This represents a 14.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,751 shares of company stock valued at $13,603,991. Insiders own 0.70% of the company's stock.

About The Cigna Group

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.